CATX

Perspective Therapeutics Inc

2.29

Oct 20 • 12:43 PM ET +0.10 (4.34%)

Healthcare Medical Devices USA Micro AMEX

Peers: AKTS TLX LNTH ATNM MOLN RADX DRTS CLRB NVS NBTX

| Held by: VTI IWM VXF IWN VTWO IBB DFAS SCHA VHT IWC

Index	RUT
Market Cap	260.83M
Enterprise Value	27.91M
Income	-116.43M
Sales	0.41M
Book/sh	2.84
Cash/sh	2.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	166
IPO	Nov 10, 2005

P/E	-
Forward P/E	-
PEG	-
P/S	636.18
P/B	0.80
P/C	1.10
P/FCF	-
EV/EBITDA	-
EV/Sales	68.08
Quick Ratio	6.61
Current Ratio	6.61
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-1.33
EPS next Y	-1.02
EPS next Q	-0.24
EPS this Y	31.00%
EPS next Y	-5.25%
EPS next 5Y	11.41%
EPS past 3/5Y	-39.72% -22.26%
Sales past 3/5Y	-56.57% -38.04%
EPS Y/Y TTM	-0.42%
Sales Y/Y TTM	-66.88%
EPS Q/Q	23.29%
Sales Q/Q	-72.07%
Earnings	Aug 10 AMC
EPS/Sales Surpr.	12.39% -10.50%

Insider Own	16.74%
Insider Trans	-2.64%
Inst Own	85.88%
Inst Trans	6.59%
ROA	-33.19%
ROE	-39.57%
ROIC	-35.64%
Gross Margin	-890.95%
Oper. Margin	-28174.08%
Profit Margin	-28467.97%
SMA20	-8.17%
SMA50	-19.65%
SMA200	-36.30%
Trades

Shs Outstand	114.09M
Shs Float	95.04M
Short Float	17.44%
Short Ratio	10.57
Short Interest	16.57M
52W High	6.16 -62.91%
52W Low	1.96 16.88%
Volatility	7.70% 7.91%
ATR (14)	0.19
RSI (14)	40.30
Beta	1.95
Rel Volume	0.99
Avg Volume	1.57M
Volume	805,543

Perf Week	0.66%
Perf Month	-23.06%
Perf Quarter	-23.06%
Perf Half Y	-50.75%
Perf YTD	-16.91%
Perf Year	-28.37%
Perf 3Y	-22.93%
Perf 5Y	-64.11%
Perf 10Y	-66.15%
Recom	1.13
Target Price	12.23
Prev Close	2.19
Price	2.29
Change %	4.34%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-26	Initiated	William Blair	Outperform
Aug-19-26	Initiated	BMO Capital Markets	Outperform	$11
Feb-19-26	Initiated	Piper Sandler	Overweight	$16
Nov-24-25	Resumed	Truist	Buy	$12
Oct-10-25	Initiated	BTIG Research	Buy	$14
Mar-13-25	Initiated	H.C. Wainwright	Buy	$10
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$15
Nov-25-24	Downgrade	BofA Securities	Buy → Neutral	$24 → $5
Oct-24-24	Initiated	UBS	Buy	$20
Oct-01-24	Initiated	Wedbush	Outperform	$25
Sep-25-24	Initiated	Truist	Buy	$21
Jul-25-24	Initiated	BofA Securities	Buy	$24
May-09-24	Initiated	Cantor Fitzgerald	Overweight

Show Previous Ratings

Oct-08-26 06:16AM	Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors (GlobeNewswire) +10.16%
Oct-07-26 06:16AM	Perspective Therapeutics Announces Acceptance of [212Pb]VMT-a-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium (GlobeNewswire)
Oct-02-26 11:46AM	Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 (GlobeNewswire)
Sep-14-26 06:16AM	Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors (GlobeNewswire)
Sep-11-26 06:00AM	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 (GlobeNewswire)
04:44PM	Loading…
Aug-10-26 04:44PM	Perspective Therapeutics: Q2 Earnings Snapshot (Associated Press) +6.00%
04:22PM	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results (GlobeNewswire)
Jul-31-26 06:30AM	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-28-26 06:30AM	Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-a-NET in GEP-NETs (GlobeNewswire)
Jul-17-26 12:22PM	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Oral Presentation at the ESMO Congress 2026 (GlobeNewswire)
Jul-08-26 06:30AM	Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor (GlobeNewswire)
Jun-03-26 02:06PM	Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial (Proactive)
06:30AM	Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-a-NET in the Meningioma Cohort of a Phase 1/2a Study (GlobeNewswire)
May-21-26 05:51PM	Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma (GlobeNewswire)
May-18-26 06:30AM	Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies (GlobeNewswire)
05:58PM	Loading…
May-11-26 05:58PM	Perspective Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:07PM	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results (GlobeNewswire)
Apr-24-26 06:30AM	Perspective Therapeutics to Provide Several Upcoming Corporate Updates (GlobeNewswire)
Apr-20-26 06:00AM	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting (GlobeNewswire) +8.33%
Apr-02-26 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-17-26 04:45PM	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the AACR Annual Meeting 2026 (GlobeNewswire) -5.17%
Mar-16-26 04:07PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results (GlobeNewswire)
Feb-17-26 08:42PM	Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress (Insider Monkey)
11:17AM	New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (PR Newswire)
07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results (GlobeNewswire)
Feb-02-26 08:35AM	Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +33.51%
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire) -11.03%
Jan-12-26 07:00AM	Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -15.14%
Jan-09-26 07:00AM	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Dec-18-25 07:00AM	Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
07:00AM	Loading…
Dec-04-25 07:00AM	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium (GlobeNewswire) +8.14%
Nov-20-25 07:00AM	Perspective Therapeutics to Participate in Upcoming December Conferences (GlobeNewswire) -7.83%
Nov-10-25 04:27PM	Perspective Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results (GlobeNewswire)
Nov-06-25 07:45AM	Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Nov-04-25 05:25PM	Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates (Zacks) -10.38%
Oct-31-25 07:00AM	Perspective Therapeutics to Participate in Upcoming November Conferences (GlobeNewswire)
Oct-29-25 08:15AM	Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-24-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-20-25 04:00AM	Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the ESMO Congress 2025 (GlobeNewswire) -28.95%
Oct-02-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors (GlobeNewswire)
Sep-15-25 07:00AM	Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma (GlobeNewswire)
Sep-04-25 07:00AM	Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer (GlobeNewswire)
Sep-03-25 07:00AM	Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors (GlobeNewswire)
Aug-26-25 07:00AM	Perspective Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
Aug-13-25 06:50AM	Perspective Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:45AM	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results (GlobeNewswire)
Aug-12-25 06:05PM	Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.99%
Aug-06-25 05:35PM	electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 07:15AM	Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates (Zacks)
Jul-24-25 12:45PM	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ESMO Congress 2025 (GlobeNewswire)
12:45PM	Perspective Therapeutics Announces Acceptance of VMT--NET Data for Presentation at the ESMO Congress 2025 (GlobeNewswire)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-15-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) -7.06%
Jun-21-25 08:00AM	Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting (GlobeNewswire)
08:00AM	Perspective Therapeutics Commences Recruitment for [212Pb]VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial (GlobeNewswire)
08:00AM	Perspective Therapeutics Commences Recruitment for [212Pb]VMT--NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial (GlobeNewswire)
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire)
May-30-25 05:21PM	Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the 2025 ASCO Annual Meeting (GlobeNewswire) -7.00%
05:21PM	Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT--NET at the 2025 ASCO Annual Meeting (GlobeNewswire)
May-21-25 11:22AM	Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential (Insider Monkey) -13.07%
May-12-25 04:43PM	Perspective Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +6.81%
04:36PM	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results (GlobeNewswire)
May-01-25 07:00AM	Perspective Therapeutics to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-29-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors (GlobeNewswire)
07:00AM	Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP- Positive Solid Tumors (GlobeNewswire)
Apr-23-25 12:25PM	Perspective Therapeutics Announces Acceptance of VMT-a-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire) +8.88%
12:25PM	Perspective Therapeutics Announces Acceptance of VMT- -NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire)
07:00AM	Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last? (Zacks)
Apr-17-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results (GlobeNewswire)
Apr-11-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma (GlobeNewswire)
Apr-09-25 12:08AM	Is Now The Time To Invest In Perspective Therapeutics (Seeking Alpha) +11.11%
Apr-02-25 09:35AM	Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround (Zacks)
Mar-31-25 07:00AM	Perspective Therapeutics to Participate in Upcoming April Investor Conferences (GlobeNewswire)
Mar-26-25 04:10PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results (GlobeNewswire) -8.10%
Mar-17-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma (GlobeNewswire)
Feb-26-25 07:00AM	Perspective Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-21-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results (GlobeNewswire)
Feb-05-25 07:00AM	Perspective Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire) +5.67%
Jan-24-25 12:18PM	Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars (Benzinga) +10.47%
07:00AM	Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
07:00AM	Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT- -NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-22-25 07:00AM	Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 (GlobeNewswire)
07:00AM	Perspective Therapeutics to Discuss Data on [212Pb]VMT- -NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 (GlobeNewswire)
Jan-14-25 08:35AM	Perspective Therapeutics provides business updates, strategic priorities (TipRanks) -5.88%
Jan-13-25 08:00AM	Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-10-25 07:00AM	Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-25 08:00AM	Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer (GlobeNewswire)
Nov-27-24 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences in December (GlobeNewswire) -6.36%
Nov-26-24 07:00AM	Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital (TipRanks) +19.24%
06:45AM	Perspective Therapeutics downgraded to Neutral from Buy at BofA (TipRanks)
Nov-21-24 07:15AM	Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium (GlobeNewswire) -51.38%
07:15AM	Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT- -NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium (GlobeNewswire)
Nov-16-24 01:26AM	Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025? (Insider Monkey)
Nov-15-24 04:08PM	Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 (GlobeNewswire) -11.66% -11.68%
04:08PM	Perspective Therapeutics to Discuss Data on [212Pb]VMT- -NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 (GlobeNewswire)
Nov-12-24 04:37PM	Perspective Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -6.94%
04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results (GlobeNewswire)
Oct-31-24 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lantheus Alpha Therapy, LLC	10% Owner	Sep 04 '26	Sale	3.15	167,149	526,051	11,273,364	Sep 08 04:51 PM
Lantheus Alpha Therapy, LLC	10% Owner	Sep 03 '26	Sale	3.11	80,783	250,896	11,440,513	Sep 08 04:51 PM
Lantheus Alpha Therapy, LLC	10% Owner	Sep 02 '26	Sale	3.11	42,129	131,219	11,521,296	Sep 04 05:00 PM
Lantheus Alpha Therapy, LLC	10% Owner	Aug 31 '26	Sale	3.14	78,145	245,610	11,599,194	Sep 04 04:58 PM
Lantheus Alpha Therapy, LLC	10% Owner	Sep 01 '26	Sale	3.12	35,769	111,574	11,563,425	Sep 04 04:58 PM
Lantheus Holdings, Inc.	10% Owner	Sep 01 '26	Sale	3.12	35,769	111,574	11,563,425	Sep 03 04:54 PM
Lantheus Holdings, Inc.	10% Owner	Aug 31 '26	Sale	3.14	78,145	245,610	11,599,194	Sep 02 04:36 PM
Hunt Jonathan Robert	Chief Accounting Officer	Nov 13 '25	Buy	2.03	11,000	22,295	59,800	Nov 17 08:01 AM
Williamson Robert F III	Director	Nov 12 '25	Buy	2.10	9,498	19,946	9,864	Nov 14 08:00 AM

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

CEO & DirectorMr. Johan M. Spoor

CFO & Principal Financial OfficerMr. Joel David Sendek

M.D.Dr. Markus Puhlmann M.B.A.

Co-Founder & Senior Scientific AdvisorDr. Michael K. Schultz Ph.D.

Executive Vice President of OperationsMr. Shane Cobb

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CATX

Perspective Therapeutics Inc

Upgrade your Finviz experience